The first one was a male MF patient in his early forties with fully remission of MF cutaneous lesions during treatment with ipilimumab for advanced melanoma [93] and the second one was the case of a 67-year-old female SS patient who highly expressed CTLA4-CD28 fusion in the cancer cells, a finding that permitting treatment with ipilimumab [94]. This evidence concerns the gene CTLA4 and synovial sarcoma.